I completed my PhD at the Université de Montreal, where my work contributed to change our understanding of phagocytosis and antigen cross-presentation (Cell 2002, Nature 2003). I then went on to pursue my post-doctoral studies at the Harvard-affiliated and world-renowned Dana-Farber Cancer Institute where my work helped redefine the resting state of immune receptor (the T cell receptor) as well as steps required for proper activation (Cell 2008, J.Exp.Med 2012). Stemming from this work I opened my lab in 2011 at the Institute for Research in Immunology and Cancer (IRIC) where our work primarily focuses on molecular and translation immunology in the field of oncology, as well as provide insightful and meaningful contributions to the work performed by our many collaborators. Stemming form our work on immune receptors, I co-founded Modulari-T with David Cotnoir-White, where I sit as the CSO. Modulari-T aims to redefine cell-based therapies by providing novel receptor architectures that enable efficient signaling and improved therapeutic outcomes. I completed my PhD at the Université de Montreal, where my work contributed to change our understanding of phagocytosis and antigen cross-presentation (Cell 2002, Nature 2003). I then went on to pursue my post-doctoral studies at the Harvard-affiliated and world-renowned Dana-Farber Cancer Institute where my work helped redefine the resting state of immune receptor (the T cell receptor) as well as steps required for proper activation (Cell 2008, J.Exp.Med 2012). Stemming from this work I opened my lab in 2011 at the Institute for Research in Immunology and Cancer (IRIC) where our work primarily focuses on molecular and translation immunology in the field of oncology, as well as provide insightful and meaningful contributions to the work performed by our many collaborators. Stemming form our work on immune receptors, I co-founded Modulari-T with David Cotnoir-White, where I sit as the CSO. Modulari-T aims to redefine cell-based therapies by providing novel receptor architectures that enable efficient signaling and improved therapeutic outcomes.

• 

  Co-founder & CSO in Modulari-T

  Sophisticated Receptors For Next-Generation Cell Therapies.